Interestingly, in the only study in which glycated hemoglobin was identical across treatment groups throughout the trial (i.e., DIGAMI-2 [58]) was also the one which reported a higher cancer-related mortality in patients randomized to insulin [60]. Here, INS is linked to cancer.